Genentech, Inc.

F. Hoffmann-la Roche Ag

Lan Wang

Chudi Obioma Ndubaku

Alan G Olivero

Robert Andrew Heald

Timothy Heffron

Steven Huy Do

Aleksandr Kolesnikov

Stephen Colin Price

Adrian Folkes

Steven T Staben

Nicole Blaquiere

Danette Dudley

Mark Jones

Huifen Chen

Steven R Magnuson

Terry Crawford

Seth F Harris

Graham Elgin Jones

Jennafer Dotson

Neville James McLean

Laurent Salphati

Sussie Lerche Krintel

Joseph P Lyssikatos

John A Flygare

Anthony A Estrada

Lewis J Gazzard

BinQing Wei

Frederick Cohen

Po-Wai Yuen

Vishal Verma

Daniel Shore

Guosheng Wu

Binqing Wei

Michael F T Koehler

Aijun Lu

Baihua Hu

Kurt Deshayes

Xingyu Lin

Yanyan Chu

BinQuing Wei

Chudi Nbdubaku

Matthew Volgraf

Adrian J Folkes

The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators

The invention provides a method of inhibiting angiogenesis in a patient by administering a compound of formula (I): 

Aminoquinazoline and pyridopyrimidine derivatives

Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Zis CRor N; Zis CRor N; Zis CRor N; Zis CRor N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Benzoxazepin PI3K inhibitor compounds and methods of use

The invention provides a method of treating cancer in a patient by administering a compound of formula (I): 

The invention provides novel compounds having the general formula: wherein A, Rand Rare as described herein, compositions including the compounds and methods of using the compounds.

Isoquinoline and naphthyridine derivatives

Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions.  Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.

Tricyclic PI3K inhibitor compounds and methods of use

The invention provides novel compounds having the general formula: 

The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds having the general formula U1-M-U2 wherein M is a linking group covalently joining R2, R3, R4 or R5 of U1 to an R2, R3, R4 or R5 group of U2; U1 and U2 have the general formula (I) and G, X1, X2, R2, R3, R3', R4, R4&#x2032; and R5, are as described herein. 

Inhibitors of IAP

Benzoxazepin P13K inhibitor compounds and methods of use

Growing community of inventors

Foster City, CA, United States of America

Lan Wang